Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rocbrutinib vs BR/R2 in relapsed/refractory non-GCB DLBCL
NCT07189065Phase 2Recruiting
- Sponsor
- Lupeng Pharmaceutical
- Start
- Nov 2025
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of rocbrutinib in diffuse large B-cell lymphoma (DLBCL), sponsored by Lupeng Pharmaceutical. Started Nov 2025; status: recruiting.
02
Drugs
rocbrutinib
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT07189065.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07189065.